A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico

Kristen Bauer, Ines O Esquilin, Alberto Santiago Cornier, Stephen J Thomas, Ana I Quintero Del Rio, Jorge Bertran-Pasarell, Javier O Morales Ramirez, Clemente Diaz, Simon Carlo, Kenneth H Eckels, Elodie Tournay, Jean-Francois Toussaint, Rafael De La Barrera, Stefan Fernandez, Arthur Lyons, Wellington Sun, Bruce L Innis, Kristen Bauer, Ines O Esquilin, Alberto Santiago Cornier, Stephen J Thomas, Ana I Quintero Del Rio, Jorge Bertran-Pasarell, Javier O Morales Ramirez, Clemente Diaz, Simon Carlo, Kenneth H Eckels, Elodie Tournay, Jean-Francois Toussaint, Rafael De La Barrera, Stefan Fernandez, Arthur Lyons, Wellington Sun, Bruce L Innis

Abstract

This was a double-blind, randomized, controlled, phase II clinical trial, two dose study of re-derived, live-attenuated, tetravalent dengue virus (TDEN) vaccine (two formulations) or placebo in subjects 1-50 years of age. Among the 636 subjects enrolled, 331 (52%) were primed, that is, baseline seropositive to at least one dengue virus (DENV) type. Baseline seropositivity prevalence increased with age (10% [< 2 years], 26% [2-4 years], 60% [5-20 years], and 93% [21-50 years]). Safety profiles of TDEN vaccines were similar to placebo regardless of priming status. No vaccine-related serious adverse events (SAEs) were reported. Among unprimed subjects, immunogenicity (geometric mean antibody titers [GMT] and seropositivity rates) for each DENV increased substantially in both TDEN vaccine groups with at least 74.6% seropositive for four DENV types. The TDEN vaccine candidate showed an acceptable safety and immunogenicity profile in children and adults ranging from 1 to 50 years of age, regardless of priming status. ClinicalTrials.gov: NCT00468858.

© The American Society of Tropical Medicine and Hygiene.

Figures

Figure 1.
Figure 1.
Subject disposition. * Withdrawals through study Month 12. N = number of subjects; AE = adverse event; ATP = according to protocol.
Figure 2.
Figure 2.
Pre-vaccination priming status, by age (total vaccinated cohort [TVC]).
Figure 3.
Figure 3.
Reverse cumulative distribution curve for dengue virus (DENV) antibody titers at Month 7 for unprimed subjects (according to protocol [ATP] cohort for immunogenicity).
Figure 4.
Figure 4.
Reverse cumulative distribution curve for dengue virus (DENV) antibody titers at Month 7 for primed subjects (according to protocol [ATP] cohort for immunogenicity).

References

    1. Centers for Disease Control and Prevention (CDC) Dengue World Health Organization (WHO) Technical Report Series, No. 932, 2006 Annex 1. Guidelines for the Production and Quality Control of Candidate Tetravalent Dengue Virus Vaccines (Live) 2012. Available at. Accessed October 8, 2013.
    1. World Health Organization (WHO) Global Strategy for Dengue Prevention and Control, 2012–2020. WHO Report. Geneva; Switzerland: 2012. WHO/HTM/NTD/VEM/2012.5.
    1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. The global distribution and burden of dengue. Nature. 2013;496:504–507.
    1. Knope K, National Arbovirus and Malaria Advisory Committee. Giele C. Increasing notifications of dengue in Australia related to overseas travel, 1991 to 2012. Commun Dis Intell Q Rep. 2013;37:e55–e59.
    1. Badurdeen S, Valladares DB, Farrar J, Gozzer E, Kroeger A, Kuswara N, Ranzinger SR, Tinh HT, Leite P, Mahendradhata Y, Skewes R, Verrall A. European Union, World Health Organization (WHO-TDR) supported IDAMS study group Sharing experiences: towards an evidence based model of dengue surveillance and outbreak response in Latin America and Asia. BMC Public Health. 2013;13:607.
    1. World Health Organization (WHO) Impact of Dengue. 2013. Available at. Accessed October 9, 2013.
    1. Centers for Disease Control and Prevention (CDC) The Dengue Update: 2010: Largest Dengue Outbreak in Puerto Rico history. 2011. Vol. 3, No. 1. Available at. Accessed March 21, 2014.
    1. Innis BL, Eckels KH. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg. 2003;69:1–4.
    1. Edelman R, Wasserman S, Bodison S, Putnak R, Eckels K, Tang D, Kanesa-Thasan N, Vaughn D, Innis B, Sun W. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg. 2003;69((Suppl)):48–60.
    1. Simasathien S, Thomas SK, Watanaveeradej V, Nisalak A, Barberousse C, Innis B, Sunn W, Putnak R, Eckels K, Hutagalung Y, Gibbons R, Zhang C, De La Barrera R, Jarman R, Chawachalasai W, Mammen M. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naïve children. Am J Trop Med Hyg. 2008;78:426–433.
    1. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP., Jr Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg. 2011;85:341–351.
    1. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, Gibbons RV, Innis BL. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg. 2013;88:73–88.
    1. Watanaveeradej V, Gibbons RV, Simasathien S, Nisalak A, Jarman RG, Kerdpanich A, Tournay E, De La Barrerra R, Dessy F, Toussaint JF, Eckels KH, Thomas SJ, Innis BL. Safety and immunogenicity of a re-derived, live-attenuated dengue virus vaccine in healthy adults living in Thailand: a randomized trial. Am J Trop Med Hyg. 2014;91:119–128.
    1. Schulz KF, Altman DG, Moher D. Consort Group CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
    1. International Committee on Harmonization Medical Dictionary for Regulatory Activities. 2014. Available at. Accessed August 1, 2014.
    1. Lee IK, Lee WH, Liu JW, Yang KD. Acute myocarditis in dengue hemorrhagic fever: a case report and review of cardiac complications in dengue-affected patients. Int J Infect Dis. 2010;14:e919–e922.
    1. Sadon N, Delers A, Jarman RG, Klungthong C, Nisalak A, Gibbons RV, Vassilev V. A new quantitative RT-PCR method for sensitive detection of dengue virus in serum samples. J Virol Methods. 2008;153:1–6.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться